anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Angiogenesis inhibitors are administered to patients in an amount effective to regulate normal, non-transformed vascularized tissue size and/or growth by regulating its vascular compartment. Examples of tissues that can be controlled include adipose tissue, intestinal polyps, muscle (including cardiac) tissue, and endometrial tissue. The response of these tissues to the angiogenesis inhibitors is dose-dependent, reversible, and common to a variety of different angiogenesis inhibitors (examples use TNP-470, angiostatin, and endostatin), based on studies in animal models of obesity, intestinal polyps, cardiac hypertrophy, and endometriosis. Initial studies conducted in an adipose tissue model (genetically obese mice and normal control mice) showed that the growth and mass of adipose tissue is under the control of microvascular endothelium. Expansion of adipose tissue was associated with endothelial cell proliferation. Inhibition of angiogenesis led to reduction in adipose tissue mass. Weight gain in animals receiving angiogenesis inhibitors was significantly restricted, in spite of increases in appetite sufficient to cause weight gain in paired-fed mice. Discontinuation of the inhibitor resulted in rapid expasion of the adipose tissue. The effect was dose-dependent, repeatedly reversible, and occurred in response to all of the inhibitors tested. Significant inhibition was also observed in both the intestinal polyp and cardiac hypertrophy animal models, using dosages of two-thirds or less than the dosages used to treat tumors. Preliminary results in an endometriosis model also show a clear trend towards decreased development of endometriosis in animals treated with angiogenesis inhibitors at a dosage of one-third the dosage used to treat tumors. No effect on normal tissue that was not proliferating, other than adipose tissue, was observed.
Control Group: No additional attempt or routine call will be made to grandmother and mothers in the control group. The questionnaires will be given to the mothers at the same time for filling the surveys after birth, one month, 3 and 6 months follow up will be done with grandmothers and mothers.
Gait disorders are a disabling feature of Parkinson's disease (PD). To avoid falls, people with PD should be able to adequately adapt their gait. This requires correct response inhibition and integration of visual information. In this small pilot study, we investigated PD-related impairments in gait adaptability and the influence of ocular disorders thereon. Compared with controls, persons with PD were less able to adapt their gait in unexpected situations (U = 21.5, p = 0.013), with only a small influence of ocular disorders on precision stepping (U = 6, p = 0.012 in the ML-direction and in the AP-direction, (U = 20, p = 0.456). This shows that people with PD have more difficulty with precision stepping than healthy controls and experience more problems with adapting their gait. We found only a small impact of ocular disorders on successfully execute precision stepping. The ability to adapt gait, particularly in challenging environmental conditions or with impaired vision, may provide a useful assessment and training option for fall prevention in PD.
<P>PROBLEM TO BE SOLVED: To easily and efficiently carry out radiographing in a patient's room and image processing of a radiographic image.  <P>SOLUTION: The patient's room, or the like, in a ward 100b is provided with a ward terminal 6a, or the like, for mediating between a portable terminal 4 which manages photographing order information and cassette ID (identification) information of a cassette corresponding to each photographed part, and an order information management device 1 storing the photographing order information. When receiving a request for the photographing order information from the portable terminal 4, the ward terminal 6a downloads the photographing order information from the order information management device 1 and transmits it to the portable terminal 4. When the photographing order information with the cassette ID information added is transmitted from the portable terminal 4, the photographing order information with the cassette ID information added is uploaded to the order information management device 1. Any ward terminal such as the ward terminal 6a is of an identical constitution, and the same data transmission/reception is possible for the portable terminal 4 connected to any ward terminal.  <P>COPYRIGHT: (C)2004,JPO
PCT No. PCT/JP95/01442 Sec. 371 Date Mar. 12, 1997 Sec. 102(e) Date Mar. 12, 1997 PCT Filed Jul. 20, 1995 PCT Pub. No. WO96/03131 PCT Pub. Date Feb. 8, 1996A percutaneously absorbable preparation which contains norethisterone, estradiol or ester thereof, each of which is highly absorbable percutaneously, can readily be stuck to the skin, and is lowly skin irritating. It is prepared by applying a pressure-sentitive adhesive layer comprising a drug and a pressure-sensitive adhesive to one side of a support. The drug comprises at least one member selected from among norethisterone, estradiol and pharmacologically acceptable esters thereof, while the adhesive comprises a copolymer composed of 20-55 mol. % of vinylpyrrolidone and 80-45 mol. % of alkyl (C4-C18) (meth)acrylate. The adhesive layer further contains a sorbifacient comprising 0.1-10 wt. % of at least one member selected from among dicarboxylic acids, hydroxy carboxylic acids, plyoxyethylene alkyl ethers and amide compounds and 5-40 wt. %, both based on the adhesive layer, of a higher fatty acid ester prepared from a C10-C18 fatty acid and a C1-C20 alcohol and also contains a cohesive force improver.
The intervention group or experimental group will receive the bicycle training intervention during the first year of the study. The intervention is a 5 day/75 minutes per day bicycle training intervention which used specialized instruction and adapted equipment to teach independent bicycle riding skills to youth aged 9-18 years with autism spectrum disorder and Down syndrome.
Cancer pain is one of the most disabling symptoms complained by cancer patients, with a crucial impact on physical and psychological well-being. Botulinum neurotoxins (BoNTs) type A and B have emerged as potential interventions for chronic pain; however, their role in these patients is still debated. Thus, this systematic review of randomized controlled trials aimed at assessing the effects of BoNT treatment for cancer pain to guide physicians in an evidence-based approach integrating BoNT in cancer care. Out of 5824 records, 10 RCTs satisfied our eligibility criteria and were included in the present work for a total of 413 subjects with several cancer types (breast, head and neck, esophageal, and thoracic/gastric cancers). While some studies demonstrated significant pain reduction and improved quality of life post-BoNT-A injections, outcomes across different cancer types were inconclusive. Additionally, several effects were observed in functioning, dysphagia, salivary outcomes, esophageal strictures, gastric emptying, and expansions. This review emphasizes the need for further standardized research to conclusively establish the efficacy of BoNT in comprehensive cancer pain management.
Beginning 4 weeks before the practice begins use of the CDB, clinicians receive training on how to use the CDB and continue to provide breast cancer surgical care per their usual care. Clinicians may also participate in an audio-recorded phone interview over 20 minutes.
The Prescribed Exercise to Reduce Recidivism After Weight Loss Pilot (PREVAIL-P) study will evaluate the effect of aerobic exercise training amount on weight maintenance following clinically significant weight loss (CWL). Overweight and obese (BMI: 25-40 kg/m2) men and women (18-65 years old) complete an OPTIFAST diet (7%-10% weight loss). Participants that obtain CWL will be subsequently randomized to aerobic exercise training consistent with the minimum physical activity guidelines (\~150 min of moderate intensity exercise) or weight maintenance guidelines (200-300 min per wk. at moderate intensity) for 9 additional months.

Specific Aim 1: To demonstrate the efficacy of the weight loss program in producing CWL and retention/adherence of the exercise intervention. Overweight and obese adults (N=39) will participate in an OPTIFAST weight loss program and supervised aerobic exercise training (\~550 metabolic equivalents minutes \[MET min. per week.\]) for 10 weeks. Participants who obtain CWL will be subsequently randomized to 16 weeks of aerobic training consistent with the minimum physical activity recommendations (\~550 MET min per week.) or weight maintenance guidelines (\~970 MET min per week). The percentage of participants that obtain at least 7% weight loss following OPTIFAST treatment, retention rates in the weight loss program, adherence to exercise levels, and changes in weight and cardiometabolic risk factors in response to the intervention will be evaluated.

Specific Aim 2: To test the hypothesis that exercise levels consistent with weight maintenance recommendations leads to greater weight maintenance after CWL compared to the minimum physical activity recommendation levels. Overweight and obese adults (N=30) enrolled in VIDANT health's OPTIFAST program and have achieved at least 7% weight loss will be randomized to 36 weeks of aerobic exercise training consistent with the minimum public health guidelines for physical activity (\~550 MET min. per week.) or weight maintenance levels (\~970 MET min per week). The effect of the intervention will be evaluated on weight (primary) as well as main secondary measures (e.g. body fat, visceral fat, lipids, lipoprotein particles size/class, insulin sensitivity, blood pressure, arterial stiffness, systemic inflammation, fitness, and quality of life). The aforementioned cardiometabolic risk factors were selected because they can be improved specifically by weight loss and thus may respond differently to weight maintenance or regain.
The validation procedure will occur over eight weeks consisting of administering eight 24-hour diary of electronic device use (24-hour ED use diary) and the Electronic Device Use Questionnaire (EDUQ) at three time points. The time points for the eight 24-hour ED use diaries will be determined by random number generator for each of the participants at baseline (https://www.random.org/), of which two will take place on weekend days, and the remainder on weekdays. The EDUQ will be completed at baseline and at the conclusion of weeks four and eight.
<P>PROBLEM TO BE SOLVED: To provide an agent, used for preventing or treating endometriosis, targeting midkine (MK) and to provide a method for examining endometriosis and to provide an examination medicine.  <P>SOLUTION: By studying the mitogen activity of MK on cultured endometrial stromal cells, it is clarified that MK stimulates the proliferation of ESC. By evaluating the MK concentration in the peritoneal fluid (PF), it is clarified that the MK level is elevated in a female with the progress of endometriosis. It is further found out that the MK concentration in the PF of a female under the therapy with GnRH agonist is significantly lower than the concentration in another group. It is indicated that MK mRNA is expressed in cells originating in peritoneal bone marrow, the peritoneal membrane and an intrauterine tissue.  <P>COPYRIGHT: (C)2008,JPO&INPIT
A dry iron-containing preparation suitable for the preparation of compositions for intramuscular injection comprises as the active constituent a complex of ferric iron with two non-toxic iron complex-forming components, one of which is a hexitol, e.g. mannitol, sorbitol, dulcitol or ibitol or a uronic acid derivable from a hexitol, or a hydroxy lower alkyl hexitol, the other being an a -hydroxycarboxylic acid, e.g. citric, tartaric, gluconic, malic or lactic acid. It may be prepared by adding an aqueous solution of a ferric compound, e.g. FeCl3 (preferred), water-soluble ferric salts, basic ferric salts or ferric compounds which form ferric hydroxide when made alkaline in the presence of dextrin, to an aqueous solution of the hexitol and carboxylic acid components optionally containing a dispersion stabilizer, e.g. dextrin, glucose, saccharose or a low molecular weight dextran fraction, the ferric solution being added portion-wise and the pH being adjusted to between 5 and 10 (preferably 7) between additions. The active material is precipitated by addition of ethanol or other non-solvent therefor and purified by repeated re-solution and precipitation, the final product either being precipitated and dried or used directly in solution for the preparation of compositions for injection.
Stress-related overeating can lead to excessive weight gain, increasing the risk of metabolic and cardiovascular disease. Mindfulness meditation has been demonstrated to reduce stress and increase interoceptive awareness and could, therefore, be an effective intervention for stress-related overeating behavior. To investigate the effects of mindfulness meditation on stress-eating behavior, meditation-naïve individuals with a tendency to stress-eat (N = 66) participated in either a 31-day, web-based mindfulness meditation training or a health training condition. Behavioral and resting-state fMRI data were acquired before and after the intervention. Mindfulness meditation training, in comparison to health training, was found to significantly increase mindfulness while simultaneously reducing stress- and emotional-eating tendencies as well as food cravings. These behavioral results were accompanied by functional connectivity changes between the hypothalamus, reward regions, and several areas of the default mode network in addition to changes observed between the insula and somatosensory areas. Additional changes between seed regions (i.e., hypothalamus and insula) and brain areas attributed to emotion regulation, awareness, attention, and sensory integration were observed. Notably, these changes in functional connectivity correlated with behavioral changes, thereby providing insight into the underlying neural mechanisms of the effects of mindfulness on stress-eating.Clinical trial on the ISRCTN registry: trial ID ISRCTN12901054.
BACKGROUND AND PURPOSE: Diet might be a modifiable factor in preventing cancer by modulating inflammation. This study aims to explore the association between the dietary inflammatory index (DII) score and the risk of bladder cancer (BC).
METHODS: A total of 112 BC patients and 292 control subjects were enrolled in a case-control trial. Additionally, we tracked a total of 109 BC patients and 319 controls, whose propensity scores were obtained from the Nutrition Examination Survey (NHANES) database spanning from 1999 to 2020. The baseline index and dietary intake data were assessed using a food frequency questionnaire (FFQ). DII scores were calculated based on the dietary intake of 20 nutrients obtained from participants and categorized into four groups. The association between the inflammatory potential of the diet and BC risk was investigated using multivariate odds ratios (ORs) and 95% confidence intervals (CIs).
RESULTS: High DII scores were associated with a pro-inflammatory diet and a higher risk of BC, with higher DII scores positively associated with a higher risk of BC (quartiles 4 vs. 1, ORs 4.89, 95% CIs 2.09-11.25 p < 0.001). Specifically, this might promote BC development by inducing oxidative stress and affecting DNA repair mechanisms. This result was consistent with the NHANES findings (quartiles 4 vs. 1, ORs 2.69, 95% CIs 1.25-5.77, p = 0.006) and further supported the association of pro-inflammatory diet and lifestyle factors with the risk of BC.
CONCLUSIONS: Diets with the highest pro-inflammatory potential were associated with an increased risk of BC. By adjusting lifestyle factors, individuals might effectively lower their DII, thereby reducing the risk of developing BC. The results are consistent with the NHANES cohort.
FIELD: medicine, immunology. SUBSTANCE: squid and cuttlefish ganglions were homogenized in water acidified with acetic acid to pH = 3.5-4.5 in the presence of 0.1% zinc chloride and mixture is kept for 24-48 h. Supernatant is obtained and subjected for sterilizing filtration. Sterile filtrate is concentrated by 5.5-fold by ultrafiltration through the porous material at separation limit 1000-5000 Da and subjected for purification in 3-fold excess of alkalinized water, pH = 9.0-10.0. The purified concentrate is concentrated again by 2-fold on the same porous material and subjected for sterilizing filtration. The preparation is pouring under sterile conditions and dried by lyophilization. Preparation can be used for immune sera production. EFFECT: simplified method, improved ecology. 3 tbl
Patients will be asked to stop taking any kind of anti-inflammatory medication from 7 days before the procedure to 2 weeks after but fasting in this group won't be required. An ultrasound guided aspiration and triamcinolone (40 mg) diluted with lidocaine without epinephrine and ropivacaine will be used to anesthetize the tissues down to the cyst (including within the cyst for steroid injections). A compression bandage will be placed locally for 7 days. Investigators will monitor any side effect from the injection and treat the patients per standard care - this can include prescription of analgesics.
Selegiline hydrochloride, USP is a levorotatory acetylenic derivative of phenethylamine. It is commonly referred to in the clinical and pharmacological literature as l-deprenyl.  
The chemical name is: (R)-(-)-N α-dimethyl-N-2- propynylphenethylamine hydrochloride. It is a white to near white crystalline powder, freely soluble in water, chloroform, and methanol, and has a molecular weight of 223.75. The molecular formula is C13H17N·HCl and the structural formula is as follows:

Each capsule, for oral administration contains 5 mg of selegiline hydrochloride. In addition, each capsules contains the following inactive ingredients: anhydrous citric acid, anhydrous lactose, colloidal silicon dioxide, microcrystalline cellulose, and magnesium stearate. The capsule shell contains gelatin, D&C Red # 28, FD&C Blue # 1, FD&C Yellow #6 and titanium dioxide and are imprinted with black ink. The ink contains the inactive ingredients: ammonium hydroxide, n-butyl alcohol, isopropyl alcohol, iron oxide black, propylene glycol and shellac.
Osteoporosis is one of the major problems in our aging society. Osteoporosis results in bone fracture in older members of the population, especially in post-menopausal women. In traditional medicine, there are many natural crude drugs that have the potential for use to treat bone diseases. So far, there is no report in literature on anti- osteoporosis (bone forming) activity of Butea species. It was thought to study the anti- osteoporotic activity of this plant. Thus, the present invention provides a pharmaceutical composition from the extracts of Butea monosperma for prevention or treatment of bone disorders, process of preparation and use thereof.
In one small study, volunteers who received 24 mg/70 kg did not demonstrate toxicity.

In another study, 36 patients with acute stroke received a loading dose of 4 mg/kg (10 mg/m2/min) of naloxone hydrochloride injection followed immediately by 2 mg/kg/hr for 24 hours. Twenty-three patients experienced adverse events associated with naloxone use, and naloxone was discontinued in seven patients because of adverse effects. The most serious adverse events were: seizures (two patients), severe hypertension (one patient), and hypotension and/or bradycardia (three patients).

At doses of 2 mg/kg in normal subjects, cognitive impairment and behavioral symptoms, including irritability, anxiety, tension, suspiciousness, sadness, difficulty concentrating, and lack of appetite have been reported. In addition, somatic symptoms, including dizziness, heaviness, sweating, nausea, and stomachaches were also reported. Although complete information is not available, behavioral symptoms were reported to often persist for 2 to 3 days.
The IMA is ligated and divided at 2 cm from its origin. Apical lymph nodes dissection is performed.
White matter injury (WMI) resulting from intracerebral hemorrhage (ICH) is closely associated with adverse prognoses in ICH patients. Although Circ-AGTPBP1 has been reported to exhibit high expression in the serum of premature infants with WMI, its effects and mechanisms in ICH-induced WMI remain unclear. This study aimed to investigate the role of circ-AGTPBP1 in white matter injury after intracerebral hemorrhage. An intracerebral hemorrhage rat model was established by injecting autologous blood into rat left ventricles and circ-AGTPBP1 was knocked down at the ICH site using recombinant adeno-associated virus, AAV2/9. Magnetic resonance imaging (MRI) and gait analysis were conducted to assess long-term neurobehavioral effects. Primary oligodendrocyte progenitor cells (OPCs) were isolated from rats and overexpressed with circ-AGTPBP1. Downstream targets of circ-AGTPBP1 in OPCs were investigated using CircInteractome, qPCR, FISH analysis, and miRDB network. Luciferase gene assay was utilized to explore the relationship between miR-140-3p and Pcdh17 in OPCs and HEK-293T cells. Finally, CCK-8 assay, EdU staining, and flow cytometry were employed to evaluate the effects of mi-RNA-140-3p inhibitor or silencing of sh-pcd17 on the viability, proliferation, and apoptosis of OPCs. Low expression of circ-AGTPBP1 alleviates white matter injury and improves neurological functions in rats after intracerebral hemorrhage. Conversely, overexpression of circ-AGTPBP1 reduces the proliferative and migrative potential of oligodendrocyte progenitor cells and promotes apoptosis. CircInteractome web tool and qPCR confirmed that circ-AGTPBP1 binds with miR-140-3p in OPCs. Additionally, miRDB network predicted Pcdh17 as a downstream target of miR-140-3p. Moreover, pcdh17 expression was increased in the brain tissue of rats with intracerebral-induced white matter injury. Furthermore, inhibiting miR-140-3p suppressed the proliferation and migration of OPCs and facilitated apoptosis through Pcdh17. Circ-AGTPBP1 promotes white matter injury through modulating the miR-140-3p/Pcdh17 axis. The study provides a new direction for developing therapeutic strategies for white matter injury.
This arm will be given sufficient dose of rocuronium. In this Arm group, rocuronium will be administered to maintain deep neuromuscular blockade \[NMB\] (train-of-four \[TOF\] count 0, post-tetanic count \[PTC\] of 1-2 twitches) until the end of surgery and the reversal of NMB will be performed by sugammadex 4 mg/kg at the end of surgery'.
The invention discloses a method for preparing an interleukin-11 semi-finished product solution, and products thereof. The method comprises the following steps of: dissolving interleukin-11 into a phosphate buffer, adding glycin, and stirring to obtain the mixed solution; adjusting the pH value of the mixed solution; supplementing injection water to fix volume, and stirring to obtain the interleukin-11 semi-finished product solution, wherein the pH value of the mixed solution is adjusted to 8.0-9.5 by using diluted alkaline or is adjusted to 1.0-6.0 by using diluted acid. The method better solves the problems of accumulation and settlement of the interleukin-11 in the preparing, sterile filtering and packaging processes of the semi-finished product. The prepared semi-finished product solution is clear and transparent, and has no opalescence, and the volume of the protein of the main drug is accurately fixed. The sterile filtration of the prepared semi-finished product solution semi-finished product solution is easy to implement, the filter membrane can not be blocked, and the accumulation and settlement can not be caused during the packaging process of the semi-finished product. The clearness of the finished product is good after redissolution, no flocky precipitate or opalescence can be produced, the stable activity is maintained, and the use quantity is reduced in clinic.